Study Reference No. - C2D02146
| Study Type | Demographic | Gender | Age | Location | Compensation |
|---|---|---|---|---|---|
| Birch Allergy | Allergy to birch tree pollen | Males and Females | 18 to 65 | Mississauga, ON | $7,760 |
Study Details |
|
Study Purpose |
The primary purpose of this study is to find out if DM-101PX is safe and can be tolerated by the study participants. The test drug DM-101PX is under development for immunotherapeutic treatment of birch pollen allergy. It will be tested in the Environmental Exposure Chamber (EEC) where you will be exposed to birch pollen in an amount which will be similar to what you would be exposed to on a high pollen day in the natural environment. |
Study Duration |
The study consists of 2 screening visits (medical and EEC screening), 10 treatment visits and an end-of-study visit. |
Study Schedule |
|
General Screening |
Currently pre-screening. Multiple dates available. Contact recruitment. |
Medical Screening |
Starts 07-September |
Study Visit(s) |
TBD in September |
Follow-Up Visit(s) |
N/A |
Other Notes |
|
Bring Valid Photo ID. Refer a Friend and you may be eligible to receive up to $100 per referral. |
|